Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Levosimendan (OR1259) is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 31.00 | |
50 mg | In stock | $ 45.00 | |
100 mg | In stock | $ 61.00 | |
200 mg | In stock | $ 103.00 | |
500 mg | In stock | $ 237.00 |
Description | Levosimendan (OR1259) is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner. |
Synonyms | OR1259, OR1855 |
Molecular Weight | 280.28 |
Formula | C14H12N6O |
CAS No. | 141505-33-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 52 mg/mL (185.5 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Levosimendan 141505-33-1 Autophagy Membrane transporter/Ion channel Metabolism Potassium Channel PDE Carbonic Anhydrase Simsndan OR-1259 OR 1855 Phosphodiesterase (PDE) inhibit OR1259 OR-1855 KcsA OR1855 Inhibitor OR 1259 inhibitor